Metabolic profile and clinical hyperandrogenism in Cushing

Hanae Rachedi; Dounia Zerrouki; Nabila Zeryouh; Amel Rania El; Siham Rouf; Hanane Latrech

doi:10.1530/endoabs.90.EP534

EP534

Prev Next

Section Contents Cite

Endocrine Abstracts (2023) 90 EP534 | DOI: 10.1530/endoabs.90.EP534

ECE2023 Eposter Presentations Diabetes, Obesity, Metabolism and Nutrition (355 abstracts)

Metabolic profile and clinical hyperandrogenism in Cushing’s disease

Hanae Rachedi ¹ , Dounia Zerrouki ¹ , Nabila Zeryouh ¹ , Rania El Amel ¹ , Siham Rouf ² & Hanane Latrech ²

Err

Author affiliations

¹Endocrinology, Diabetology and Nutrition Department, University Hospital Center Mohammed VI, Oujda, Morocco; ²Endocrinology, Diabetology and Nutrition Department, Laboratory of Epidemiology, Clinical Research and Public Health, Faculty of Medicine and Pharmacy, Mohamed I University, Oujda, Morocco.

Introduction: Cushing’s disease is a rare condition that represents the most common cause of endogenous Cushing’s syndrome. Its severity is due to cardiovascular complications, with high morbi-mortality rates. This study aims to evaluate the specific features of metabolic disorders in females having Cushing’s disease and presenting a clinical hyperandrogenism.

Materials and methods: Retrospective and descriptive study, including 12 female patients with Cushing’s disease presenting a clinical hyperandrogenism, recruited in the Endocrinology-Diabetology-Nutrition department of university hospital center Mohammed VI of Oujda between 2016 and 2022. Statistical analysis was performed by SPSS version 21 software.

Results: The mean age was 30.3±11.8 years, with age ranging from 14 to 54 years. The average BMI was 32.7±8.1 kg/m², obesity was observed in 41.6% of our patients. The mean waist circumference was 107.4±13 cm. Dyslipidemia was found in 66.7% of patients: mixed dislipidemia was noted in 58.3% of them, hypercholesterolemia was found in 91.6% and hypoHDLemia was described in 83.3% of cases. In addition 33.3% of our patients were diabetics with a mean HBA1c of 6.5±1.3%, requiring insulin therapy in 50% and metformin in monotherapy in 50% of cases. Twenty-five percent of our patients had an association of diabetes and arteriel hypertension. In total, 58.3% of our patients had a metabolic syndrome.

Discussion-conclusion: In Cushing’s disease, hypercortisolism leads, through a combination of effects on the liver, muscles, adipose tissue and pancreas, to an augmentation of gluconeogenesis and an alteration of insulin sensitivity, causing glucidic metabolism disorders. The therapeutic approach to these patients must be comprehensive, including the control of associated cardiometabolic diseases, in order to reduce morbidity and mortality rates. (1)

Bibliography: 1-Tritos NA, Biller BM. Cushing’s disease. Handb Clin Neurol. 2014;124:221-34. Doi: 10.1016/B978-0-444-59602-4.00015-0. PMID: 25248590.